Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary A correction was issued regarding the phase 2 SWOG S1512 trial, which investigated anti-PD-1 therapy (pembrolizumab) for unresectable desmoplastic melanoma. The correction Read More
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary The SWOG S1512 phase 2 trial investigated pembrolizumab (anti-PD-1 therapy) in patients with unresectable desmoplastic melanoma (DM), a rare and aggressive subtype. The study Read More
Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study Summary This study investigated the effectiveness of combining transarterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC), targeted therapy, Read More
1 Million+ Views and Counting..!
It has been 7 years since it was launched in late July 2018, and it is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
